Daiichi Sankyo (OTCMKTS:DSNKY – Get Free Report) was upgraded by stock analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a report released on Wednesday, Zacks reports.
Separately, Jefferies Financial Group cut shares of Daiichi Sankyo from a “buy” rating to a “hold” rating in a research note on Thursday, July 30th. Two research analysts have rated the stock with a Hold rating. According to MarketBeat.com, the stock currently has a consensus rating of “Hold”.
Read Our Latest Stock Report on DSNKY
Daiichi Sankyo Price Performance
Daiichi Sankyo stock opened at $17.11 on Wednesday. Daiichi Sankyo has a 1 year low of $14.98 and a 1 year high of $24.77. The firm has a 50 day moving average price of $17.75 and a 200 day moving average price of $17.51. The company has a market cap of $31.87 billion, a price-to-earnings ratio of 17.46, a PEG ratio of 1.64 and a beta of -0.10. The company has a debt-to-equity ratio of 0.29, a quick ratio of 1.96 and a current ratio of 2.92.
Daiichi Sankyo (OTCMKTS:DSNKY – Get Free Report) last issued its quarterly earnings results on Friday, October 30th. The company reported $0.29 EPS for the quarter, topping the consensus estimate of $0.21 by $0.08. The firm had revenue of $3.77 billion during the quarter, compared to analyst estimates of $3.58 billion. Daiichi Sankyo had a net margin of 12.13% and a return on equity of 16.31%. Sell-side analysts predict that Daiichi Sankyo will post 1.05 earnings per share for the current year.
About Daiichi Sankyo
Daiichi Sankyo is a Japan-based pharmaceutical company that researches, develops, manufactures and markets medicines. Formed in 2005 through the merger of Sankyo and Daiichi Pharmaceutical, the company has a particular focus on oncology and also develops treatments in areas such as cardiovascular disease and other serious conditions. Its portfolio includes Enhertu (trastuzumab deruxtecan), an antibody-drug conjugate developed in collaboration with AstraZeneca, as well as medicines such as Lixiana (edoxaban) and Vanflyta (quizartinib).
Further Reading
- Five stocks we like better than Daiichi Sankyo
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Daiichi Sankyo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Daiichi Sankyo and related companies with MarketBeat.com's FREE daily email newsletter.
